Related references
Note: Only part of the references are listed.Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates
MaryBeth B. Culp et al.
EUROPEAN UROLOGY (2020)
The role of JNK in prostate cancer progression and therapeutic strategies
Ruiyuan Xu et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours
Mikiya Ishihara et al.
BMC CANCER (2020)
Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer
Elham Kalantari et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2019)
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
Eda K. Holl et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2019)
Immunotherapy for Prostate Cancer
Nicholas J. Venturini et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2019)
Strong Expression of Cancertestis Antigens CTAG1B and MAGEA3 Is Correlated with Unfavourable Histopathological Features and MAGEA3 Is Associated with Worse Progression-Free Survival in Urothelial Bladder Cancer
Eva Maria Lausenmeyer et al.
UROLOGIA INTERNATIONALIS (2019)
MAGE-A antigens as targets for cancer immunotherapy
Erik Schooten et al.
CANCER TREATMENT REVIEWS (2018)
Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions
Catherine E. Handy et al.
FUTURE ONCOLOGY (2018)
Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks
Michael C. Comiskey et al.
CURRENT ONCOLOGY REPORTS (2018)
Epigenetic regulation of MAGE family in human cancer progression-DNA methylation, histone modification, and non-coding RNAs
Yishui Lian et al.
CLINICAL EPIGENETICS (2018)
A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy
Elizabeth K. Duperret et al.
CLINICAL CANCER RESEARCH (2018)
MAGEA3 Expression in Cutaneous Squamous Cell Carcinoma Is Associated with Advanced Tumor Stage and Poor Prognosis
Melody Abikhair et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
MAGE-A family is involved in gastric cancer progression and indicates poor prognosis of gastric cancer patients
Yishui Lian et al.
PATHOLOGY RESEARCH AND PRACTICE (2017)
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Definition of Grading Patterns and Proposal for a New Grading System
Jonathan I. Epstein et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Study of NGEP expression pattern in cancerous tissues provides novel insights into prognostic marker in prostate cancer
Monireh Mohsenzadegan et al.
BIOMARKERS IN MEDICINE (2015)
The MAGE protein family and cancer
Jenny L. Weon et al.
CURRENT OPINION IN CELL BIOLOGY (2015)
MAGE-A3: an immunogenic target used in clinical practice
Ali Esfandiary et al.
IMMUNOTHERAPY (2015)
Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells
Aaron P. Rapoport et al.
CLINICAL CANCER RESEARCH (2014)
Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer
Simon Laban et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer
Sayeema Daudi et al.
PLOS ONE (2014)
Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis
Monireh Mohsenzadegan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
Wim H. J. Kruit et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
CETN1 is a cancer testis antigen with expression in prostate and pancreatic cancers
John J. Kim et al.
BIOMARKER RESEARCH (2013)
Expression and Immunotherapeutic Targeting of the SSX Family of Cancer-Testis Antigens in Prostate Cancer
Heath A. Smith et al.
CANCER RESEARCH (2011)
MAGE-A3 expression is an adverse prognostic factor in diffuse large B-cell lymphoma
Irma Olarte et al.
HEMATOLOGY (2011)
Cancer/Testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy
Takumi Shiraishi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
The melanoma-associated antigen-A3,-A4 genes: relation to the risk and clinicopathological parameters in breast cancer patients
Yousri M. Hussein et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2011)
Expression of Cancer/Testis Antigens in Prostate Cancer Is Associated With Disease Progression
Takahito Suyama et al.
PROSTATE (2010)
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2009)
Expression of Cancer-Testis Antigens MAGE-A3/6 and NY-ESO-1 in Non-Small-Cell Lung Carcinomas and Their Relationship with Immune Cell Infiltration
Sang Hyun Kim et al.
LUNG (2009)
MAGE-C1/CT-7 expression in plasma cell myeloma: Sub-cellular localization impacts on clinical outcome
M. Tinguely et al.
CANCER SCIENCE (2008)
A multimarker real-time RT-PCR for MAGE-A gene expression allows sensitive detection and quantification of the minimal systemic tumor load in patients with localized cancer
Ingo Mecklenburg et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2007)
Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in squamous cell carcinoma of the penis
Tvrtko Hudolin et al.
UROLOGY (2006)
Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue
T Hudolin et al.
PROSTATE (2006)
Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer
AO Gure et al.
CLINICAL CANCER RESEARCH (2005)
MAGE-A3 is a frequent tumor antigen of metastasized melanoma
C Roeder et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2005)
High-grade prostatic intraepithelial neoplasia
DG Bostwick et al.
MODERN PATHOLOGY (2004)